NO20051379L - Triazaspiro [5.5]undeknaderivater og legemidler omfattende de samme som den aktive bestanddel - Google Patents

Triazaspiro [5.5]undeknaderivater og legemidler omfattende de samme som den aktive bestanddel

Info

Publication number
NO20051379L
NO20051379L NO20051379A NO20051379A NO20051379L NO 20051379 L NO20051379 L NO 20051379L NO 20051379 A NO20051379 A NO 20051379A NO 20051379 A NO20051379 A NO 20051379A NO 20051379 L NO20051379 L NO 20051379L
Authority
NO
Norway
Prior art keywords
allergic
diseases
aspergillosis
triazaspiro
signaling
Prior art date
Application number
NO20051379A
Other languages
English (en)
Norwegian (no)
Inventor
Shiro Shibayama
Yoshikazu Takaoka
Rena Nishizawa
Kenji Sagawa
Masayoshi Matsuo
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20051379L publication Critical patent/NO20051379L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
NO20051379A 2002-09-18 2005-03-16 Triazaspiro [5.5]undeknaderivater og legemidler omfattende de samme som den aktive bestanddel NO20051379L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002270849 2002-09-18
PCT/JP2003/011834 WO2004026873A1 (ja) 2002-09-18 2003-09-17 トリアザスピロ[５.５]ウンデカン誘導体およびそれらを有効成分とする薬剤

Publications (1)

Publication Number Publication Date
NO20051379L true NO20051379L (no) 2005-06-17

Family

ID=32024865

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051379A NO20051379L (no) 2002-09-18 2005-03-16 Triazaspiro [5.5]undeknaderivater og legemidler omfattende de samme som den aktive bestanddel

Country Status (15)

Country Link
US (1) US20050267114A1 (ja)
EP (1) EP1541574A4 (ja)
JP (1) JPWO2004026873A1 (ja)
KR (1) KR20050057408A (ja)
CN (1) CN1688577A (ja)
AU (1) AU2003272879A1 (ja)
BR (1) BR0314304A (ja)
CA (1) CA2497903A1 (ja)
MX (1) MXPA05002771A (ja)
NO (1) NO20051379L (ja)
PL (1) PL376154A1 (ja)
RU (1) RU2005111225A (ja)
TW (1) TW200413372A (ja)
WO (1) WO2004026873A1 (ja)
ZA (1) ZA200502222B (ja)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003271057A1 (en) * 2002-09-18 2004-04-08 Ono Pharmaceutical Co., Ltd. Novel crystals of triazaspiro(5.5)undecane derivative
JP4736043B2 (ja) * 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
JPWO2004094424A1 (ja) * 2003-04-21 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその用途
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
EP1874295A4 (en) 2005-04-20 2009-08-12 Merck & Co Inc benzothiophene
US7872024B2 (en) 2005-04-20 2011-01-18 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
AU2006240248A1 (en) 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JPWO2006129679A1 (ja) * 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US8158825B2 (en) 2005-06-24 2012-04-17 Merck Sharp & Dohme Corp. Modified malonate derivatives
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
AU2007225836A1 (en) * 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
JP2009535333A (ja) 2006-04-26 2009-10-01 メルク エンド カムパニー インコーポレーテッド 二置換アニリン化合物
US8119652B2 (en) 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
JP2009544611A (ja) 2006-07-20 2009-12-17 メルク エンド カムパニー インコーポレーテッド ヒストン脱アセチル化酵素阻害剤としてのリン誘導体
EP2064199A1 (en) * 2006-09-08 2009-06-03 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP2010515729A (ja) 2007-01-10 2010-05-13 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
EP2128163A1 (en) * 2007-01-25 2009-12-02 Takeda Pharmaceutical Company Limited Spiro-ring compound
BRPI0811562A2 (pt) 2007-05-07 2014-12-09 Novartis Ag Compostos orgânicos
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2692153A1 (en) 2007-06-27 2009-01-08 Richard W. Heidebrecht, Jr. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
TWI439462B (zh) 2007-12-10 2014-06-01 Novartis Ag 作為ｅｎａｃ阻抑劑之螺環胍化合物
CN102112130A (zh) 2008-06-10 2011-06-29 诺瓦提斯公司 作为上皮钠通道阻滞剂的吡嗪衍生物
WO2010009196A1 (en) * 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
JP2012529432A (ja) 2009-06-05 2012-11-22 リンク・メディスン・コーポレーション アミノピロリジノン誘導体及びその使用
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
CN105078978A (zh) 2009-08-17 2015-11-25 因特利凯公司 杂环化合物及其用途
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
WO2011143444A2 (en) * 2010-05-14 2011-11-17 President And Fellows Of Harvard College Diphenylbutypiperidine autophagy inducers
CN103097385B (zh) 2010-07-14 2016-08-03 诺华股份有限公司 Ip受体激动剂杂环化合物
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
WO2013105065A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
CN104169282B (zh) 2012-01-13 2016-04-20 诺华股份有限公司 Ip受体激动剂的盐
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
RU2502738C2 (ru) * 2012-02-07 2013-12-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" 1,6'-ДИАРИЛ-3-АРОИЛ-4-ГИДРОКСИ-1',3'-ДИМЕТИЛСПИРО[ПИРРОЛ-2,5'-ПИРРОЛО[2,3-d]ПИРИМИДИН]-2',4',5(1Н,1'Н,3'Н)-ТРИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
EA033571B1 (ru) 2014-04-24 2019-11-06 Novartis Ag Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
WO2015162456A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
WO2016140501A1 (en) * 2015-03-04 2016-09-09 Kainos Medicine, Inc. Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
WO2020246487A1 (ja) * 2019-06-04 2020-12-10 第一三共株式会社 ジスピロジケトピペラジン構造を有する化合物
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
JOP20220044A1 (ar) 2019-08-28 2023-01-30 Novartis Ag مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031364A1 (en) * 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2001040227A1 (fr) * 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif
US7285552B2 (en) * 2001-03-19 2007-10-23 Ono Pharmaceuticals Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
MXPA03008529A (es) * 2001-03-19 2004-06-30 Ono Pharmaceutical Co Derivado de triazaspiro [5.5]undecano y composicion farmaceutica que comprende el mismo como ingrediente activo.
JP2002348288A (ja) * 2001-05-28 2002-12-04 Ono Pharmaceut Co Ltd スピロ複素環誘導体およびそれらを有効成分とする薬剤
JPWO2003035074A1 (ja) * 2001-10-23 2005-02-10 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体とチトクロムｐ４５０アイソザイム３ａ４阻害剤および／またはｐ糖タンパク質阻害剤との組み合わせからなる医薬
WO2003104233A1 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
AU2003266152A1 (en) * 2002-09-13 2004-04-30 University Of Maryland Biotechnology COMPOSITIONS FOR INDUCING INCREASED LEVELS OF Beta-CHEMOKINES AND METHODS OF USE THEREFOR
AU2003271057A1 (en) * 2002-09-18 2004-04-08 Ono Pharmaceutical Co., Ltd. Novel crystals of triazaspiro(5.5)undecane derivative
AU2003282821B2 (en) * 2002-10-11 2010-12-16 University Of Maryland, Baltimore Carbohydrate-based synthetic vaccines for HIV
EP1553098A1 (en) * 2002-10-18 2005-07-13 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
WO2004092169A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
US20070270429A1 (en) * 2003-05-06 2007-11-22 Shiro Shibayama Function Inhibitor of Effector Cell
BRPI0410360A (pt) * 2003-05-16 2006-08-01 Univ Maryland Biotech Inst composições para a sub-regulação da expressão de ccr5 e métodos para seu uso
CA2573951A1 (en) * 2003-07-18 2005-01-27 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
IL157398A0 (en) * 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists

Also Published As

Publication number Publication date
RU2005111225A (ru) 2005-08-27
CA2497903A1 (en) 2004-04-01
CN1688577A (zh) 2005-10-26
PL376154A1 (en) 2005-12-27
AU2003272879A1 (en) 2004-04-08
US20050267114A1 (en) 2005-12-01
MXPA05002771A (es) 2005-06-06
JPWO2004026873A1 (ja) 2006-01-19
TW200413372A (en) 2004-08-01
WO2004026873A1 (ja) 2004-04-01
KR20050057408A (ko) 2005-06-16
ZA200502222B (en) 2005-12-28
BR0314304A (pt) 2005-07-26
EP1541574A4 (en) 2007-06-20
EP1541574A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
NO20051379L (no) Triazaspiro [5.5]undeknaderivater og legemidler omfattende de samme som den aktive bestanddel
NO20054244L (no) Nitrogeninneholdende heterocykliske derivater og legemidler inneholdende de samme som den aktive bestanddel
TW200616956A (en) Nitrogen-containing heterocyclic compound and medicament containing the same as active ingredient
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
EA200500143A1 (ru) Азолидинонвинильные производные конденсированного бензола
EA200500610A1 (ru) Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
DK1942108T3 (da) Forbindelse indeholdende basisk gruppe samt anvendelse deraf
NO20051036L (no) 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander
WO2000050020A3 (en) Use of sulfamate derivatives for treating impulse control disorders
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
NO20055316L (no) Nye heterocykliske forbindelser som er nyttige ved behandling av inflammatoriske og allergiske forstyrrelser, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger som inneholder slike
EA200870344A1 (ru) Азотсодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента
NO20052546L (no) Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon.
ATE378332T1 (de) Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon
CY1112042T1 (el) Ιικοι αναστολεις
DE69632728D1 (de) 1,4-disubstituierte piperidinderivate
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
WO2004018463A3 (en) Pyridyl substituted heterocycles useful for treating or preventing hcv infection
JP2006527727A5 (ja)
AR072113A1 (es) Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas
EP1621540A4 (en) HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
DK1404656T3 (da) Derivater af benzimidazol til behandling af sygdomme forbundet med en aktivering af mikroglia, såsom inflammatoriske, allergiske, inficerende eller autoimmune sygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application